Piramal Pharma Limited has announced that the USFDA conducted a Pre-Approval Inspection (PAI) of Piramal Pharma Limited's PPDS Ahmedabad facility from 10th July 2024 to 12th July, 2024.

The inspection was completed successfully with Zero Form - 483 observations and No Action Indicated (NAI) designation.

Successful completion of this wholistic inspection at PPDS Ahmedabad facility, will now enable access to our high-end analytical capabilities to our customers for their clinical and commercial batches from an FDA approved site.

The company remains committed to maintain the highest standards of compliance.